Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now

被引：31
作者：
Rosove, Michael H. [1 ]
Grody, Wayne W. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
ANNALS OF INTERNAL MEDICINE | 2009年 / 151卷 / 04期
关键词：
COAGULATION-FACTOR; CYP2C9; GENOTYPE; BLEEDING RISK; VKORC1; GENE; ANTICOAGULATION; POLYMORPHISMS; RESISTANCE; ASSOCIATION; SENSITIVITY; THERAPY;
D O I：
10.7326/0003-4819-151-4-200908180-00009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The U. S. Food and Drug Administration modified warfarin labeling in 2007 to suggest, but not mandate, pharmacogenetic testing. Genetic analysis is now commercially available. However, results predict only one third of all dosing variation, the value of testing in reducing bleeding and thrombosis rates remains unproved, and cost-effectiveness is not established. Careful consideration of clinical factors that influence dosing, conscientious prothrombin time monitoring, and sage dosage adjustment remain paramount in warfarin management. Further study is required before routine warfarin pharmacogenetic testing can be recommended.
引用
收藏
页码：270 / W95
页数：5
相关论文
共 31 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
*AM COLL CHEST PHY, 2008, CHEST, V133, pS160
[3]   Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].
Aquilante, CL ;
Langaee, TY ;
Lopez, LM ;
Yarandi, HN ;
Tromberg, JS ;
Mohuczy, D ;
Gaston, KL ;
Waddell, CD ;
Chirico, MJ ;
Johnson, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302
[4]   CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study [J].
Caraco, Y. ;
Blotnick, S. ;
Muszkat, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) :460-470
[5]  
*COUM GEN INV, 2007, CIRCULATION, V116, P2563
[6]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[7]   Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation [J].
Eckman, Mark H. ;
Rosand, Jonathan ;
Greenberg, Steven M. ;
Gage, Brian F. .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (02) :73-U31
[8]   Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues [J].
Gage, Brian F. ;
Lesko, Lawrence J. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 25 (01) :45-51
[9]   Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I [J].
Harrington, DJ ;
Underwood, S ;
Morse, C ;
Shearer, MJ ;
Tuddenham, EGD ;
Mumford, AD .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) :23-26
[10]   Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].
Higashi, MK ;
Veenstra, DL ;
Kondo, LML ;
Wittkowsky, AK ;
Srinouanprachanh, SL ;
Farin, FM ;
Rettie, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698
1234